Product Description
a fully human FGFR2 monoclonal antibody
Mechanisms of Action: FGFR Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-132218 |
JapicCTI-132218 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2016-03-31 |
|||
NCT01881217 |
NCT01881217 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2016-03-18 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|